Serum osteopontin as a prognostic marker in patients with lung cancer

Vasiliki Petta (Athens, Greece), Vasiliki Petta, Stelios Loukides, Konstantinos Kostikas, Georgios Papatheodorou, Kyriaki Cholidou, Yiannis Tomos, Spyridon Papiris, Nikolaos Koulouris, Petros Bakakos

Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Session: Lung cancer: prognostic factors and features of oncogene-driven tumours
Session type: Thematic Poster Session
Number: 4246

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Vasiliki Petta (Athens, Greece), Vasiliki Petta, Stelios Loukides, Konstantinos Kostikas, Georgios Papatheodorou, Kyriaki Cholidou, Yiannis Tomos, Spyridon Papiris, Nikolaos Koulouris, Petros Bakakos. Serum osteopontin as a prognostic marker in patients with lung cancer. Eur Respir J 2015; 46: Suppl. 59, 4246

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013

Osteopontin levels in sputum supernatant and serum of patients with lung cancer: Does coexistent COPD make the difference?
Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement
Year: 2013


Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014

Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016


MUC1 gene polymorphism and serum KL-6 in lung adenocarcinoma
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015

Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015


The impact of pulmonary rehabilitation on preoperative inflammatory markers in lung cancer patients
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013

Prognostic value of preoperative C-reactive protein in resectable non-small cell lung cancer - 5-years prospective study
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014

The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015

Procalcitonin serum levels in patients with stage IV non-small cell lung cancer in first line of chemotherapy
Source: International Congress 2016 – Clinical aspects of lung cancer
Year: 2016

Expression and clinical significance of S100 calcium binding protein A2 in lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016

Epigenetic alterations in the circulating DNA from blood of patients with COPD and lung cancer
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013

The evaluation of biological and clinical significance of alpha-1 antitrypsin in non-small cell lung cancer
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015

Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015

Prognostic affect of the chronic obstructive pulmonary disease on the local-advanced stage non-small cell lung cancer
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014

Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014


Are serum leptin levels a prognostic factor in advanced lung cancer?
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015

Metabolic signatures associated with lung cancer using serum samples. Influence of hemolysis
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014


Neutrophil to lymphocyte ratio (NLR) as a predictor of poor prognosis in advanced non-small cell lung cancer
Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Year: 2016


Lactat-dehydrogenase, C-reactive protein and white blood cell count are prognostic factors in advanced small cell lung cancer (SCLC)
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014